Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Bone Neoplasms 1

Interventions

montanide ISA 51 1liposomal doxorubicin 1cc-486 1Taxes 1Standard of Care 1Radiosurgery 1Radiation 1Quality of Life 1Practice Guidelines as Topic 1Patient Reported Outcome Measures 1Palliative Care 1Paclitaxel 1Observation 1Molecular Diagnostic Techniques 1Lomustine 1Irinotecan 1Interleukin-2 1Injections 1Immunotherapy 1Gemcitabine 1Etoposide 1Etanercept 1Drug Therapy 1Doxorubicin 1Cyclophosphamide 1Carboplatin 1Biological Therapy 1Azacitidine 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × Etanercept × Thoracic × Clear all
NCT00127387 2012-06-26

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

The University of Texas Health Science Center at San Antonio

Phase 2/3 Terminated
54 enrolled
GenitourinarySarcomaThoracic

Bone Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡